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Hyperlipidaemia, Obesity and Drug Misuse in a
Diabetic Clinic
R. B. GOLDBERG, 1. BERSOHN, B. 1. JOFFE, L. H. KRUT, H. C. SEFTEL
SUMMARY
A study of middle-aged and elderly patients attending a
diabetic clinic has revealed a disturbing state of affairs.
Hyperlipidaemia and obesity were very common but little
attention was paid to implementing appropriate dietary
regimens. Management was largely confined to the con-
trol of hyperglycaemia by using oral hypoglycaemic agents,
especially combinations of sulphonylureas and diguanides.
This situation is deplored. Firstly, it ignores the cor-
rection of factors which are as important, if not more so,
than hyperglycaemia, in regard to the development of the
most lethal complication of maturity-onset diabetes, namely
occlusive atherosclerosis. Secondly, it substitutes for die-
tary therapy, which is physiological, treatment by drugs
which are potentially harmful. It is probable that a similar
situation obtains in many other diabetic clinics.
S. A fr. Med. J., 48, 277 (1974).
We present the results of a study of insulin-independent
patients attending a diabetic clinic, in which we measured
serum cholestrol and triglyceride levels, and examined
their relationship to the factors of age, sex, body mass,
form of therapy, and degree of diabetic control. The find-
ings are not new, but they strikingly illustrate the conse-
quences of neglecting the principles of comprehensive
diabetic care.
THE CUNIC, PATIENTS AND METHODS
The Diabetic Clinic at the Johannesburg Hospital is
held once a week, and patients are seen by appointment at
intervals of one to two months. At each visit the mass
and blood pressure are recorded, and the urine is
examined for glucose and protein with Clinitest tablets
and Albustix strips, respectively. Two days before the
visit the blood sugar level is measured (ferricyanide
method in the AutoAnalyzer) in a post-breakfast speci-
men. Tests for urinary ketones are done when glycosuriil
Diabetic Clinic, Johannesburg Hospital and South African
Institute for Medical Research, Johannesburg
R. B. GOLDBERG, B.se., M.B. n.CJ!.
I. BERSOHN, n.se., "LB. n.eH., F.H.C. PATH.
B. I. ]OFFE, M.B. B.eH., M.R.C.P.
L. H. KRUT, M.B. CH.n., M.D.
H. C. SEFTEL, n.se., M.B. n.CH., D.l\'1ED.
Date received: 13 August 1973.
is heavy. Regular clinic attenders number about SOO and
they are served by 10 doctors.
Dietary advice has followed conventional lines. Diets
are prescribed which aim at nutritional balance and
desirable body mass. Sugar and foods rich in sugar
are banned, starch, fat and fruit are allowed in reduced
amounts, while protein and m"Jst vegetables are unres-
tricted. Advice is given on proper spacing of meals and
on the effects of exercise. A dietitian is available, but
because of pressure of work she is unable to offer a
regular service. To encourage adherence to the d;et we
rely mainly on regular weighing, and interrogation and
exhortation by the doctors.
Between September 1971 and ] une 1972 we studied
170 White patients selected at random from regular
attenders who were more than 35 years old, whose duration
of diabetes was at least one year, and 'vho were not
clinically nephrotic, myxoedematous, jaundiced or severely
uraemic. One hundred and thirty-f;ve patients were on
treatment with diet or oral agents and are the subjects of
this study. The remaining 35 patients were receiving
insulin; this group was too small for meaningful analysis
and is not considered further.
Serum triglyceride' and total cholesterol' levels were
estimated in fasting venous samples.
Body mass was expressed as a percentage of the
ideal body weights (lBW) listed in Ciba-Ge;gy Scientific
Tables (7th edition). Three groups of patients were defined:
non-obese, ± loq~ lBW; moderately obese, I1 - 25'10 IBW;
and markedly obese, more than 25°~ 1BW.
The degree of diabetic control was assessed by examining
all the blood and urine sugar recordings during the period
of one year previous to study. Control was regarded as
'good' if the majority (more than two-thirds) of post-
prandial blood sugar levels were less than 175 mg/100
ml and the majority of urine specimens contained not
more than I + sugar; 'moderate' if the majority of blood
sugar values were between 175 and 250 mg/l 00 ml and
glycosuria was not more than 3+; and 'poor' if the
majority of blood and urine specimens contained more
sugar than 250 mg/lOO ml and 3+, respectively.




All but 6 of the 135 patients were more than 45 years
old. Serum lipid levels were similar in patients aged
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were twice as many females as males. Serum cholesterol
levels were similar in men and women. The females had
higher triglyceride values, but the variation in both sexes
was very large and the difference was significant only
at the 5 ~~ level (Table Il). The lipid data were therefore
pooled for the remaining analyses.







Fig. 2. Distribution of serum triglyceride levels in insulin-
independent diabetics.
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and moderate in 29%, the corresponding figures for men
being 23 % and 39% (P<O,OO I for the difference in
frequency of severe obesity between the sexes). Mean
triglyceride, but not cholesterol, levels rose with increasing
body mass (r = +0,21; P<0,05).
Serum Lipid Distribution TABLE 11/. BODY MASS AND SERUM LIPID LEVELS(MEANS -+- SO)
Mean (± SO) cholesterol and triglyceride levels were
251 (± 52) and 203 (± 147) mg/IOO ml, respectively.
Hypercholesterolaemia, defined as a cholesterol level
greater than 250 mg/JOO ml, was present in 45% of cases
(Fig. 1) and hypertriglyceridaemia, defined as a triglycer-
ide level greater than 150 mgjlOO ml, in 58% (Fig. 2).






















Serum Lipids and Diabetic Control (Table IV)
Serum Lipids and Body Mass .(Table Ill)
Obesity was found in 81 % of patients, this being
moderate in 31 % and severe in 50%. No less than 91 %
of the women were overweight. This was severe in 62%
Diabetic Triglyceride Cholesterol
control % of cases (mg/l00 ml) (mg/l00 ml)
Poor 7 434 -+- 399 265 -+- 75
Moderate 17 205 -+- 107 238 -+- 41
Good 76 183 -+- 101 252 -+- 54
TABLE IV. DIABETIC CONTROL AND SERUM LIPID LEVELS
(MEANS -+- SO)
Control of the blood sugar level was good in the
majority of patients. Mean triglyceride levels were highest
in the small minority of poorly controlled diabetics, but
did not differ significantly from values in the two Better-
controlled groups.
Serum Lipids and FoOD of Therapy (Table V)
Only 8% of patients were on treatment with diet
alone. The remainder received a sulphonylurea (mainly
tolbutamide or chlorpropamide) or a biguanide (metformin
or phenformin), and, nearly half were treated with a
combination of a sulphonylurea and a biguanide. The
mean triglyceride level was lowest in the patients on diet
alone but did not differ significantly from the values in
the other treatment groups. The cholesterol level in the
10050 200 250 300 350+
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patients treated with biguanides was significantly lower
than In cases receiving sulphonylureas (P<O,OI) or sul-
phonylurea-biguanide combinations (P<O,05).
TABLE V. FORM OF THERAPY AND SERUM LIPID LEVELS
(MEANS -+- SD)
Triglyceride Cholesterol
Treatment % of cases (mg!100 ml) (mg/l00 ml)
Diet 8 153 -+- 50 274 -+- 89
Biguanide 11 205 -+- 94 222 -+- 37
Sulphonylurea 32 193 -+- 86 258 -+- 42
Sulphonylurea 49 219 -+- 194 248 -+- 54
+ biguanide
DISCUSSION
Viewed academically, our observations on serum lipids
in maturity-onset diabetics were unremarkable. In essence,
hypertriglyceridaemia and hypercholesterolaemia were
common; triglyceride levels rose moderately with increasing
body mass, which probably explains why the women, who
were more obese than the men, had somewhat higher
values; triglyceride levels tended to be higher in poorly
controlled patients but this was not statistically significant:
and lipid levels did not correlate with the type of therapy
used except that patients treated with biguanides had
lower cholesterol values than those receiving sulphonyl-
ureas. Similar findings have been reported by others in
respect of hyperlipidaemia prevalence'" and its relation-
ship to mass; control"" and form of treatment."
Practically, however, this study has revealed a state of
affairs which is a serious indictment of the management
of diabetics in the clinic. Specifically, there are three
matters for concern. Firstly, the prevalence of hyperlipi-
daemia was high. The frequency of raised lipid levels
may not be much higher in maturity-onset diabetics than
in normoglycaemic controls,'" but this does not make the
situation acceptable in view of the serious prognostic
significance of hypertriglyceridaemia and hypercholestero-
laemia." Secondly, and perhaps even more important,
most of the patients were obese and fully one half were
severely so. Thirdly, very few were on treatment with
diet alone; most were receiving oral hypoglycaemic agents
and nearly half were being treated with a combination of
a sulphonylurea and a biguanide. Few patients appeared to
haye been given a proper trial of treatment by diet alone
before being placed on these agents. Since in most cases
the control of hyperglycaemia was satisfactory, the mean-
ing of all this is clear: management of diabetic patients
was largely concentrated on lowering the blood sugar with
oral drugs and treatment of other aspects was neglected or
overlooked.
This situation is to be deplored because it ignores the
correction of factors which on present evidence appear
to be as, if not more, important than hyperglycaemia in
regard to the development of the complication responsible
for most of the morbidity and mortality in diabetics,
namely occlusive atherosclerosis. It is generally agreed
that -this disorder, especially coronary artery involvement,
occurs earlier, is more severe and progr:sses more rapidly
in diabetics than in non-diabetics. The reasons for this are
complex and not well understood but it is doubtful
whether hyperglycaemia per se is the whole explanation.
For example, critical analyses and careful investigations
have failed to demonstrate a convincing relationship
between the incidence of cardiovascular disease and the
control of hyperglycaemia. lI ,,,
Whatever the reasons, the proper management of diabetes
must involve not only the correction of hyperglycaemia
but also the elimination or reduction of afl factors known
to increase the risk, or adversely affect the prognosis, of
occlusive atherosclerosis, including physical inactivity,
gluttony, obesity, hypercholesterolaemia, hypertriglyceri-
daemia, hypertension and smoking. Of central importance
is correct dieting. In general, maturity-onset diabetics re-
quire a diet which, firstly, is low in calories and aimed at
achieving normal body mass, normoglycaemia and normal
serum triglyceride levels. Carbohydrates may have to be
particularly restricted in patients whose triglyceride res-
ponse to ingestion of this nutrient is markedly excessive.",H
Secondly, the ratio of polyunsaturated to saturated fat
should be high and aime9 at attaining and maintaining
normal serum cholesterol levels. That such diets are
practicable and capable of achieving the aims outhned
over prolonged periods has been demonstrated in recent
stud'es." There is al,o evidence that such diets may in
fact reduce the incidence of cardiovascular disease, even
when started for the first time in middle-aged subjects."
Although this has still to be shown in the diabetic popula-
tion, the find'ngs are sufficiently encouraging to stimulate
a much more vigorous approach to the implementation
of dietary measures than is commonly the case at present.
We must re-emphasise the principle that oral hypo-
glycaemic agents must never be used as a substitute for
treatment by diet. They should only be considered when
diet has failed or is unlikely to control hyperglycaemia
adequately. If tablets are introduced, diet must be con-
tinued. There are several good reasons for this advice.
Apart from the fact that oral agents have adverse effects.
including severe hypoglycaemia, and once started are
usually continued indefinitely, there is no good evidence
that they do anything to reduce the incidence of vascular
disease. In fact, as is now well known, a major finding
of the University Group Diabetes Program (UGDP) study
was that patients treated with diet plus the sulphonylurea,
tolbutamide, or diet plus the biguanide, phenformin, had
significantly higher cardiovascular mortality rates than
patients treated with diet plus a placebo. These findings
have been much criticised," but the UGDP study has been
the best of its kind and its findings have been equally
vigorously defended."
The reasons why oral hypoglycaemic agents might be
associated with an increased cardiovascular mortality are
not clear. In regard to the sulphonylureas, pertinent points
include the fact that their administration tends to be
associated with mass gain: that, as shown here and
in a long-term double-blind study,' they may not lower
serum triglyceride or cholesterol levels despite correction
of hyperglycaemia, and that apart from their hypoglycae-
mic action, they have a variety of pharmacological effects,




(Byvoegsel-SlIid-Afrikaanse Tydskrif vir Laboratorillm- en Kliniekwerk)
13 Februarie 1974
et al.'" found that sulphonylureas in concentrations that are
attained clinically exerted positive inotropic and chrono-
tropic effects on animal myocardial preparations; in patients
with coronary artery disease such stimulation might be
deleterious. It is true that the biguanides have been
reported to reduce serum lipid levels'· and body mass'
but their mode of action is incompletely understood, some
of their effects are unphysiological," their triglyceride-
lowering effect is variable,"'" and it is not clear how
much better they are than diet alone in correcting hyper-
lipidaemia or obesity. Indeed, in the UGDP study the
cardiovascular mortality of patients in the phenformin-
treated group was higher than that observed in any of
the other treatment groups." In this regard it is note-
worthy that the phenformin-treat~d patient~ exhibited a
rise in arterial blood pressu,e, albeit mild, \',hich continued
throughout the observation period of 41- years; by contrast,
in patients receiving insulin or placebo, a small fall in
pressure occurred." Finally, if both sulphonylureas and
biguanides are potentially noxious, the pos~ibility exists
that given in combination their toxicity may be additive
if not synergistic. All in all, while we are fully aware
that the last word on the oral agents has still to be said,
we believe that for the present they should be u:ed with
gre3.t circumspection, and never instead of dietary mea-
sures which are physiological and harmless. In fact. one
diabetic clinic in the USA, as a direct result of the UGDP
findings, has gone so far as to abandon the use of
phenformin and sulphonylureas almost completely, and
was able to achieve, satisfactory control with diet alone
in 60% of 200 middle-aged patients.'"
Our clinic, then, despite its name and aims, is not a
diabetic clinic, if by that we mean an organisation which
provides a system of comprehensive care for the diabetic
sufferer. We have found that its activities are largely con-
cerned with prescribing pills, especially in combination.
with the principal objective of controlling the raised blood
sugar level. It is therefore more accurately described as
a 'hyperglycaemic clinic'. Important aspects, such as obesity
and hyperlipidaemia and their serious sequelae and con-
comitants, have been largely ignored.
However, we do not believe that our experience IS
unique. In fact, we wonder whether the majority of so-
called diabetic clinics are not in a similar position. It is
the principal objective of this exercise in self-flagellation
to stimulate other clinics to examine critically their own
practice and record. We do not underestimate the diffi-
culties of providing a proper service for diabetics but we
should be able to do better.
We should like to thank the South African Medical Re-
search Council for supporting this study.
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